Oragenics (NYSE:OGEN) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a research report report published on Thursday. The firm issued a sell rating on the stock.

Oragenics Trading Up 0.4 %

Shares of Oragenics stock opened at $0.26 on Thursday. The stock has a market capitalization of $3.12 million, a price-to-earnings ratio of -0.04 and a beta of 0.85. The firm’s 50-day moving average price is $0.29 and its two-hundred day moving average price is $0.35. Oragenics has a 1-year low of $0.24 and a 1-year high of $3.43.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.